Hologic

Women's-health specialist medical-devices company and the dominant manufacturer in breast imaging globally. Hologic's 2011 FDA PMA approval for the Selenia Dimensions 3D tomosynthesis system established digital breast tomosynthesis (DBT) as a clinical category and made Hologic the reference point for DBT hardware architecture — specifically the 15° narrow-angle tomosynthesis sweep that defines the Hologic approach. Outside mammography Hologic operates in bone densitometry (DXA), breast biopsy, molecular diagnostics, and surgical products.

Company history

1985 — founded as Diagnostic Health Services; renamed Hologic shortly after.
2006 — acquired R2 Technology (mammography CAD).
2006 — acquired Suros Surgical Systems (breast biopsy — the ATEC vacuum-assisted biopsy line that pairs with current DBT platforms).
2007 — acquired Lorad (mammography — origin of the Selenia platform).
2008 — acquired Cytyc Corporation (liquid-based cytology, ThinPrep).
2008 — acquired Third Wave Technologies (molecular diagnostics, HPV testing).
February 2011 — received FDA PMA approval for the Selenia Dimensions 3D system — the first commercial digital breast tomosynthesis system in the United States. Established Hologic as the clinical reference point for DBT.
2012 — acquired Gen-Probe ($3.75 billion) — major expansion of the molecular-diagnostics portfolio (Panther platform).
2017 — acquired Cynosure (aesthetic / medical energy devices); later divested in 2019.
2020–2022 — molecular-diagnostics business scaled during the COVID-19 PCR testing era; revenue and capital position strengthened significantly.
2023 — 3Dimensions with Clarity HD detector is the current mammography flagship; Selenia Dimensions remains in active production alongside.

Product lines

Breast imaging (mammography + biopsy)

Hologic Selenia (2D) — legacy 2D FFDM.
Selenia Dimensions family — 2D + 3D (first-generation DBT).
Selenia Dimensions 2D — 2D-only sibling.
Selenia Dimensions 3D — 2011 FDA PMA DBT.
3Dimensions (Genius 3D) — current DBT flagship on the Clarity HD detector with C-View / Intelligent 2D / 3DQuorum.
Affirm Prone Biopsy System — dedicated prone stereotactic / DBT-guided breast biopsy.
Affirm upright biopsy attachment — retrofit for Dimensions / 3Dimensions gantries.
ATEC vacuum-assisted breast biopsy device line (via Suros acquisition).

Bone densitometry

Horizon DXA family (Horizon A, Ci, W).

Molecular diagnostics (non-imaging; noted for context)

Panther / Panther Fusion platforms.
ThinPrep liquid-based cytology.

Surgical products (non-imaging)

NovaSure endometrial ablation; MyoSure hysteroscopic tissue removal.

Market position

Mammography — dominant US install base. Roughly ~70% US mammography market share per industry market-share reports. Leader on DBT clinical evidence via MRMC reader studies and screening-outcome publications.
Bone densitometry — top-tier (Horizon family) with GE Lunar iDXA as primary competitor.
Breast biopsy — dominant in dedicated prone biopsy (Affirm Prone).
Molecular diagnostics — major player on Panther platform for women's-health assays (HPV, STI, respiratory).
No presence in CT / MRI / ultrasound / PET / interventional X-ray / radiation oncology — Hologic is a specialist by design.

Clinical / regulatory anchors

MQSA — Hologic's mammography systems are MQSA-accreditable (MQSA).
PMA pathway — Selenia Dimensions 3D (2011) is the reference FDA PMA for DBT.
ACR accreditation — required for mammography screening / diagnostic programs; ACR Accreditation.
Narrow-angle DBT (15°) — Hologic's architectural philosophy. Contrast Siemens' 50° wide-angle on MAMMOMAT Revelation.

GE HealthCare — mammography competitor (Senographe Pristina); DXA competitor (Lunar iDXA).
Siemens Healthineers — mammography competitor (MAMMOMAT family).
Fujifilm — mammography competitor (ASPIRE Cristalle).
Screening Mammography
Diagnostic Mammography
Stereotactic breast biopsy
DXA screening
Hologic Discovery / QDR
Hologic Horizon Wi
Hologic Affirm Upright Biopsy